SCHEMBL25317058

SCHEMBL25317058

CN1CCc2cc(F)ccc2S1(=O)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 3/20 0.44
GRIA2 P42262 3/20 0.44
GRIA3 P42263 3/20 0.44
GRIA4 P48058 3/20 0.44
NOTUM Q6P988 1/20 0.43
SRD5A1 P18405 5/20 0.39
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 2/20 0.37
ESR1 P03372 1/20 0.37
MEN1 O00255 1/20 0.36
ACHE P22303 1/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CAPN1 P07384 1/20 0.35
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26668007 0.81 NOTUM (0.41) NOTUMSRD5A1ALDH1A1ESR1ACHE
SCHEMBL7603160 0.75 ALDH1A1 (0.33) GRIA1GRIA2GRIA3GRIA4ALDH1A1
SCHEMBL12536870 0.75 DRD2 (0.48) L3MBTL1ACHECA1CA2CA12
SCHEMBL1777226 0.73 PIK3C3 (0.44) GRIA1GRIA2GRIA3GRIA4ALDH1A1
SCHEMBL1903261 0.72 DRD1 (0.50) NOTUMALDH1A1L3MBTL1DRD2DRD3
SCHEMBL25904287 0.72 MAPK1 (0.44) CA1CA2CA9
SCHEMBL25903936 0.72 HRH3 (0.44) ALDH1A1L3MBTL1KMT2AMEN1HTR2A
SCHEMBL25316710 0.71 GPR119 (0.41) ALDH1A1CA1CA12CA9
SCHEMBL15834027 0.70 ESR1 (0.38) NOTUMALDH1A1KMT2AESR1MEN1
SCHEMBL26667868 0.70 BRD4 (0.35) SRD5A1CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR GRIA1 1889/4885GRIA2 2781/4885GRIA3 2168/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR GRIA1 1889/4885GRIA2 2781/4885GRIA3 2168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.